Latest Ratios: P/E Ratio -2.5x · EV/EBITDA N/A · ROE -0.5%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $49M | $33M | $34M | $46M | $66M | $87M | $120M | — | — |
| Enterprise Value | $-4295049754 | $-4311278060 | $27M | $25M | $28M | $36M | $101M | — | — |
| P/E Ratio → | -2.46 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.01 | 0.01 | 1.62 | 1.13 | 1.17 | 1.22 | 6.08 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.5% | -0.5% | -66.9% | -32.9% | -22.3% | -27.1% | -57.2% | -655.0% | — |
| ROA | -0.3% | -0.3% | -60.0% | -31.1% | -21.5% | -26.2% | -54.2% | -258.0% | -383.8% |
| ROIC | -1.2% | -1.2% | -100.6% | -70.4% | -55.3% | -90.7% | -3063.2% | — | — |
| ROCE | -0.5% | -0.5% | -71.4% | -36.9% | -22.6% | -27.5% | -56.9% | -655.0% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.66 | -0.34 | -0.53 | -0.66 | -0.72 | -0.97 | -1.31 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -70.63 | — | — | — | — |
Net cash position: cash ($4.4B) exceeds total debt ($79M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.40 | 2.40 | 5.83 | 16.18 | 20.99 | 31.26 | 36.64 | 2.52 | 0.68 |
| Quick Ratio | 2.40 | 2.40 | 5.83 | 16.18 | 20.99 | 31.26 | 36.64 | 2.52 | 0.68 |
| Cash Ratio | 2.25 | 2.25 | 5.54 | 15.42 | 19.72 | 30.40 | 34.81 | 2.52 | 0.68 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 1.1% | 3.8% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 1.1% | 3.8% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $11M | $11M | $11M | $11M | $11M | $6M | $6M | $6M |
Clinical Trial Funding Dependency
As reported in financial statements, LTRN's P/B ratio of 0.01 suggests the market is heavily discounting the company's book value, likely reflecting investor skepticism regarding the long-term commercial viability of the RADR platform in the absence of any current revenue or positive earnings per share.
The negative P/E of -2.46 is characteristic of a pre-revenue biotech firm where traditional valuation multiples fail to capture the optionality of the clinical pipeline. Investors should monitor whether the current valuation represents a distressed entry point or a rational adjustment to the company's persistent cash burn and lack of near-term commercial catalysts.
Based on the company's reported figures, ROIC has trended downward from -18.6% in 2023Q4 to -0.2% in 2026Q1, indicating that the firm is currently unable to generate positive returns on its invested capital while it continues to fund expensive, non-revenue-generating clinical trials.
The sharp decline in ROIC appears to be driven by the sustained intensity of R&D spending relative to the shrinking asset base. This trend suggests that the company's capital allocation strategy is currently focused on survival and pipeline advancement rather than immediate efficiency, which warrants further investigation into the expected timing of milestone-based returns.
According to recent SEC filings, the current ratio has plummeted from 16.18 in 2023Q4 to 1.87 in 2026Q1, signaling a significant reduction in the company's immediate liquidity buffer as it continues to exhaust its cash reserves to support ongoing oncology-focused drug development programs.
While a current ratio of 1.87 remains technically above the threshold of immediate distress, the rapid downward trajectory suggests that the company's runway is narrowing significantly. Investors should be wary of the potential for further dilutive equity offerings, as the current liquidity position appears insufficient to sustain long-term operations without external capital infusions.
As noted in historical financial data, the use of P/E or EV/EBITDA ratios is fundamentally misapplied to LTRN, as these metrics obscure the value of the RADR platform's intellectual property and the potential for future milestone-based licensing revenue that is not yet reflected in the income statement.
Analysts should instead focus on the 'cash runway' and the 'time-to-insight' for new drug candidates as more accurate proxies for operational health. Relying on traditional earnings-based multiples for a pre-revenue biotech firm risks ignoring the underlying value of the data-driven discovery platform, which is the primary driver of the company's long-term competitive positioning.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LTRN stock.
Lantern Pharma Inc.'s current P/E ratio is -2.5x. This places it at the 50th percentile of its historical range.
Lantern Pharma Inc.'s return on equity (ROE) is -0.5%. The historical average is -34.5%.
Based on historical data, Lantern Pharma Inc. is trading at a P/E of -2.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.